A.N.M. Wymenga

1.6k total citations
41 papers, 1.1k citations indexed

About

A.N.M. Wymenga is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, A.N.M. Wymenga has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in A.N.M. Wymenga's work include Frailty in Older Adults (6 papers), Neuroendocrine Tumor Research Advances (6 papers) and Cancer survivorship and care (6 papers). A.N.M. Wymenga is often cited by papers focused on Frailty in Older Adults (6 papers), Neuroendocrine Tumor Research Advances (6 papers) and Cancer survivorship and care (6 papers). A.N.M. Wymenga collaborates with scholars based in Netherlands, Germany and United States. A.N.M. Wymenga's co-authors include Elisabeth G.E. de Vries, M.L.G. Janssen‐Heijnen, Huub Maas, Marcel G. M. Olde Rikkert, Pax H.B. Willemse, Ido P. Kema, Barbro Eriksson, J.W.R. Nortier, M. B. Jacobsen and Kjell E. Öberg and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

A.N.M. Wymenga

39 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A.N.M. Wymenga Netherlands	19	617	323	244	240	235	41	1.1k
Donald Poon Singapore	10	314 0.5×	331 1.0×	141 0.6×	103 0.4×	150 0.6×	14	774
L Balducci United States	7	590 1.0×	132 0.4×	396 1.6×	291 1.2×	44 0.2×	10	1.2k
Carmen L. Wilson United States	24	370 0.6×	78 0.2×	147 0.6×	160 0.7×	189 0.8×	63	1.6k
Richard Gregg Canada	18	732 1.2×	303 0.9×	33 0.1×	510 2.1×	199 0.8×	37	1.5k
Emmanuel Mitry France	21	1.5k 2.4×	184 0.6×	164 0.7×	600 2.5×	57 0.2×	70	2.1k
Can-Lan Sun United States	18	773 1.3×	75 0.2×	370 1.5×	312 1.3×	49 0.2×	18	2.2k
Jean Pierre Droz France	15	235 0.4×	69 0.2×	91 0.4×	217 0.9×	98 0.4×	24	1.0k
G. Albrand France	16	498 0.8×	120 0.4×	518 2.1×	389 1.6×	22 0.1×	44	1.5k
Jean-Philippe Durand France	19	593 1.0×	72 0.2×	154 0.6×	212 0.9×	25 0.1×	50	1.2k
Frédéric Pamoukdjian France	14	285 0.5×	63 0.2×	363 1.5×	207 0.9×	38 0.2×	42	917

Countries citing papers authored by A.N.M. Wymenga

Since Specialization

Citations

This map shows the geographic impact of A.N.M. Wymenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.N.M. Wymenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.N.M. Wymenga more than expected).

Fields of papers citing papers by A.N.M. Wymenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.N.M. Wymenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.N.M. Wymenga. The network helps show where A.N.M. Wymenga may publish in the future.

Co-authorship network of co-authors of A.N.M. Wymenga

This figure shows the co-authorship network connecting the top 25 collaborators of A.N.M. Wymenga. A scholar is included among the top collaborators of A.N.M. Wymenga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.N.M. Wymenga. A.N.M. Wymenga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Böhringer, Stefan, Hans J.M. Smit, Pepijn Brocken, et al.. (2024). Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective. Lung Cancer. 196. 107950–107950. 3 indexed citations

Herpen, Carla M.L. van, et al.. (2019). Caregivers’ burden and fatigue during and after patients’ treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study. Supportive Care in Cancer. 27(11). 4145–4154. 23 indexed citations

Bongers, Bart C., Frans H. de Jongh, Michiel Eijsvogel, et al.. (2018). The effects of prehabilitation versus usual care to reduce postoperative complications in high-risk patients with colorectal cancer or dysplasia scheduled for elective colorectal resection: study protocol of a randomized controlled trial. BMC Gastroenterology. 18(1). 29–29. 39 indexed citations

Palen, Job van der, et al.. (2016). Willingness to accept chemotherapy and attitudes towards costs of cancer treatment; A multisite survey study in the Netherlands.. PubMed. 74(7). 292–300. 3 indexed citations

Peters, Marlies, et al.. (2015). How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death. Palliative & Supportive Care. 14(3). 241–249. 3 indexed citations

Noll, Ruud van der, Willem M. Smit, A.N.M. Wymenga, et al.. (2015). Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational New Drugs. 33(6). 1197–1205. 8 indexed citations

Janssen‐Heijnen, M.L.G., et al.. (2013). Tolerance and benefits of treatment for elderly patients with limited small-cell lung cancer. Journal of Geriatric Oncology. 5(1). 71–77. 18 indexed citations

Hamaker, Marije E., Caroline Seynaeve, A.N.M. Wymenga, et al.. (2013). Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group. The Breast. 23(1). 81–87. 108 indexed citations

Reyners, A.K.L., Linda de Munck, Frans Erdkamp, et al.. (2012). A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology. 23(11). 2896–2902. 34 indexed citations

10.

Biesma, Bonne, A.N.M. Wymenga, Andrew Vincent, et al.. (2011). Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin–gemcitabine or carboplatin–paclitaxel: NVALT-3 a phase III study. Annals of Oncology. 22(7). 1520–1527. 79 indexed citations

11.

Horst‐Schrivers, Anouk N.A. van der, A.N.M. Wymenga, H. Marike Boezen, et al.. (2008). Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours. Neuroendocrinology. 89(2). 231–236. 16 indexed citations

12.

Maas, Huub, M.L.G. Janssen‐Heijnen, Marcel G. M. Olde Rikkert, & A.N.M. Wymenga. (2007). Comprehensive Geriatric assessment and its clinical impact in oncology. European Journal of Cancer. 43(15). 2161–2169. 136 indexed citations

13.

Schaapveld, Michael, et al.. (2005). Soft tissue sarcoma: why not treated?. Critical Reviews in Oncology/Hematology. 54(1). 77–83. 9 indexed citations

14.

Oonk, Maaike H.M., Joanne A. de Hullu, Harry Hollema, et al.. (2003). The value of routine follow‐up in patients treated for carcinoma of the vulva. Cancer. 98(12). 2624–2629. 37 indexed citations

15.

Wymenga, A.N.M. & Dirk Th. Sleijfer. (2002). Management of Hot Flushes in Breast Cancer Patients. Acta Oncologica. 41(3). 269–275. 7 indexed citations

16.

Stokman, Monique A., Fred K. L. Spijkervet, A.N.M. Wymenga, et al.. (2002). Quantification of oral mucositis due to radiotherapy by determining viability and maturation of epithelial cells. Journal of Oral Pathology and Medicine. 31(3). 153–157. 18 indexed citations

17.

Wymenga, A.N.M.. (2001). Treatment of cancer in old age, shortcomings and challenges. The Netherlands Journal of Medicine. 59(5). 259–266. 27 indexed citations

18.

Wymenga, A.N.M.. (1999). Lessons from an unusual case: malignancy associated hypercalcemia, pancreatitis and respiratory failure due to ARDS. The Netherlands Journal of Medicine. 54(1). 27–30. 3 indexed citations

19.

Wymenga, A.N.M., et al.. (1998). Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. European Journal of Cancer. 34(8). 1293–1294. 25 indexed citations

20.

Wymenga, A.N.M., Winette T.A. van der Graaf, J. Wils, et al.. (1996). A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Annals of Oncology. 7(5). 505–510. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact